Lipid-lowering therapy in primary prevention: where will we be 10 years from now

29 August 2017 (17:42 - 18:00)

Organised by:

About the speaker

Professor Alberico Catapano

IRCCS - MultiMedica, Milan (Italy)

4 More presentations in this session

Presentation thumbnail

State of the Art: cholesterol-lowering therapy for primary and secondary prevention

Doctor J. Robinson (Iowa, US)

Presentation thumbnail

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes mellitus: a systematic review and meta-analysis with over 10,000 patients

Doctor L. Carvalho (Brasilia, BR)

Abstract Slides Video

Presentation thumbnail

Effect of the magnitude of LDL lowering on the incidence of cataract among patients treated with statins or PCSK9 antibodies

Doctor J. Kostis (New Brunswick, US)

Abstract Slides Video

Presentation thumbnail

Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients

Doctor A. Endo (Izumo, JP)

Abstract Slides Video

Access the full session

Session thumbnail

Cholesterol-lowering therapy for primary and secondary prevention

The Event

ESC Congress 2017

29 August 2017 17:42 CET

You may be interested in

Webinar

Risk assessment and lipid management in primary prevention

11 April 2024

Congress Presentation

NATURE-LEGACY: Long term legacy benefit of Lowering LDL and SBP

1 September 2025

Practice Tools

How to manage blood cholesterol in primary and secondary prevention

16 May 2019

Webinar

LDL-C reduction postACS: strike early and strike strong

15 November 2021

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources